Frontlight ResearchEarly access
Taking people in United StatesEarly phase 1
Aspirin Dosing in Pregnancy
Key facts
- Who runs it
- NYU Langone Health
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 30 people, planned
- Started
- 27 Apr 2026
- Expected to end
- 20 Feb 2028
- Type of study
- Interventional
- Treatments tested
- Aspirin
- Record updated
- 18 May 2026
Who can take part
- Age
- 18 years to 50 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Pregnant people prior to 17 weeks
- Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
- Age 18-50 years
- Singleton viable gestation
- Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors
Who cannot take part
- Antithrombotic or antiplatelet therapy
- Allergy or intolerance to aspirin
- Undergoing glucose challenge test (GCT) at time of blood draw
- Anemia (hemoglobin <10 g/dl) or thrombocytopenia (platelet count <100,000), or thrombocytosis (platelet count >600,000)
- Known hemorrhagic diathesis
- Planned delivery outside of NYU
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Where in United States
- NYU Langone HealthNew York, United StatesContact: Christina A. Penfield, MD, MPHTaking people
About the trial
What the trial wants to find out
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
The group in the trial
- Twice daily dosing of AspirinTreatment being tested
Participants will take 81mg Aspirin orally, twice daily (162mg total) for 4 weeks and then return to the dosing regimen as prescribed by the discretion of their treating physician.
Treatment: Aspirin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Aspirin Dosing and Platelet Phenotype in Pregnancy
- Criteria questions
- Built from NCT07525635, who can take part
- Record updated
- 18 May 2026